소아 급성림프모구백혈병 및 비호지킨림프종 환자에서 고용량 methotrexate 투여 후 배설지연
Delayed Elimination After High-dose Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: High doses of methotrexate (MTX) are often used in various chemotherapy protocols to treat acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL) in children, but its delayed elimination increases the occurrence of adverse events, such as bone marrow suppression. The aim of this study was to investigate the elimination of MTX at 24 and 48 hours. Methods: We retrospectively analyzed electronic medical records of ALL or NHL pediatric patients who received 5 g/m2 MTX infusion over 24 hours (between June, 2012 and July, 2018) at the Yonsei University Health System, Korea. The delayed elimination of MTX concentrations was assessed with 100 or 150 μM MTX at 24 hours, and 2 or 5 μM at 48 hours. Results: Among the 85 MTX cycles administered, 23 cycles were classified in delayed elimination group, and 62 cycles showed normal elimination. At 24 hours, the delayed elimination group with MTX concentration > 100 μM showed higher percentage than group with MTX concentration < 100 μM (45.8% vs. 19.7%, p = 0.015). However, no differences were observed at 150 μM MTX (p = 0.66). At 48 hours, the delayed elimination was higher than the normal elimination at both concentration baselines (p < 0.001 at 2 μM, p = 0.024 at 5 μM). Conclusions: MTX concentrations greater than 100 μM show high probability of delayed elimination at 24 hours. When MTX levels are above normal, leucovorin and hydration regimens should be continued to prevent delayed elimination.
Abstract
Background: High doses of methotrexate (MTX) are often used in various chemotherapy protocols to treat acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL) in children, but its delayed elimination increases the occurrence of adverse events, such as bone marrow suppression. The aim of this study was to investigate the elimination of MTX at 24 and 48 hours. Methods: We retrospectively analyzed electronic medical records of ALL or NHL pediatric patients who received 5 g/m2 MTX infusion over 24 hours (between June, 2012 and July, 2018) at the Yonsei University Health System, Korea. The delayed elimination of MTX concentrations was assessed with 100 or 150 μM MTX at 24 hours, and 2 or 5 μM at 48 hours. Results: Among the 85 MTX cycles administered, 23 cycles were classified in delayed elimination group, and 62 cycles showed normal elimination. At 24 hours, the delayed elimination group with MTX concentration > 100 μM showed higher percentage than group with MTX concentration < 100 μM (45.8% vs. 19.7%, p = 0.015). However, no differences were observed at 150 μM MTX (p = 0.66). At 48 hours, the delayed elimination was higher than the normal elimination at both concentration baselines (p < 0.001 at 2 μM, p = 0.024 at 5 μM). Conclusions: MTX concentrations greater than 100 μM show high probability of delayed elimination at 24 hours. When MTX levels are above normal, leucovorin and hydration regimens should be continued to prevent delayed elimination.
참고문헌 (25)
- Csordas K, "Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia", Anticancer Drugs, 24(2), pp.189~197 (2013)
- Cerminara Z, "A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration", J Oncol Pharm Pract (2017)[DOI]
- Mao J, "Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies", Neoplasma, 61(1), pp.77~82 (2014)
- Xu W, "Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China", J Pediatr Hematol Oncol, 29(10), pp.688~693 (2007)
- Howard SC, "Preventing and Managing Toxicities of High-Dose Methotrexate", Oncologist, 21(12), pp.1471~1482 (2016)
- Yanagimachi M, "Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy", Int J Hematol, 98(6), pp.702~707 (2013)
- Larsen EC, "Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232", J Clin Oncol, 34(20), pp.2380~2388 (2016)
- Schultz KR, "Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study", J Clin Oncol, 27(31), pp.5175~5181 (2009)
- Winter SS, "Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization", J Clin Oncol, 36(29), pp.2926~2934 (2018)
- Reiss SN, "Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia", Ann Hematol, 95(12), pp.2009~2015 (2016)
- Fabresse N, "Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate", Ther Drug Monit, 40(1), pp.76~83 (2018)
- Svahn T, "Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia", Pediatr Blood Cancer, 64(7) (2017)
- Bielack SS, "Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial", J Clin Oncol, 33(20), pp.2279~2287 (2015)
- Wiczer T, "Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity", J Oncol Pharm Pract, 22(3), pp.430~436 (2016)
- Schwartz GJ, "A simple estimate of glomerular filtration rate in full-term infants during the first year of life", J Pediatr, 104(6), pp.849~854 (1984)
- Schwartz GJ, "A simple estimate of glomerular filtration rate in adolescent boys", J Pediatr, 106(3), pp.522~526 (1985)
- Bhojwani D, "Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia", J Clin Oncol, 32(9), pp.949~959 (2014)
- Skarby T, "High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)", Cancer Chemother Pharmacol, 51(4), pp.311~320 (2003)
- Santucci R, "Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors", Anticancer Res, 30(3), pp.963~965 (2010)
- Tiwari P, "Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate", Pediatr Hematol Oncol, 32(8), pp.576~584 (2015)
- Ranchon F, "Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?", Hematol Oncol, 36(2), pp.399~406 (2018)
- Ramsey LB, "Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance", Oncologist, 23(1), pp.52~61 (2018)
- Traivaree C, "The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients", Cancer Manag Res, 10, pp.4471~4478 (2018)
- Carlos D. Flombaum, "Management of Patients with Acute Methotrexate Nephrotoxicity with High-Dose Leucovorin", Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 38(7), pp.714~724 (2018), Wiley[DOI]
- Cohen IJ, "Defining the appropriate dosage of folinic acid after highdose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system", J Pediatr Hematol Oncol, 26(3), pp.156~163 (2004)